nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—Gefitinib—Vandetanib—thyroid cancer	0.714	1	CrCrCtD
Iloperidone—HTR2C—Sorafenib—thyroid cancer	0.0403	0.235	CbGbCtD
Iloperidone—CYP3A7—Sorafenib—thyroid cancer	0.0263	0.153	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0263	0.153	CbGbCtD
Iloperidone—CYP3A5—Sorafenib—thyroid cancer	0.0197	0.115	CbGbCtD
Iloperidone—CYP1A2—Sorafenib—thyroid cancer	0.0147	0.0854	CbGbCtD
Iloperidone—CYP3A4—Vandetanib—thyroid cancer	0.0128	0.0742	CbGbCtD
Iloperidone—CYP2D6—Sorafenib—thyroid cancer	0.0121	0.0704	CbGbCtD
Iloperidone—CYP3A4—Sorafenib—thyroid cancer	0.00769	0.0447	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—thyroid cancer	0.00734	0.0427	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—thyroid cancer	0.00467	0.0271	CbGbCtD
Iloperidone—Aphthous stomatitis—Sorafenib—thyroid cancer	0.00184	0.0198	CcSEcCtD
Iloperidone—Nephrolithiasis—Vandetanib—thyroid cancer	0.00159	0.0172	CcSEcCtD
Iloperidone—Endocrine disorder—Vandetanib—thyroid cancer	0.00154	0.0166	CcSEcCtD
Iloperidone—Hypothyroidism—Sorafenib—thyroid cancer	0.00134	0.0145	CcSEcCtD
Iloperidone—Cataract—Vandetanib—thyroid cancer	0.00134	0.0145	CcSEcCtD
Iloperidone—Haemoglobin decreased—Sorafenib—thyroid cancer	0.00125	0.0135	CcSEcCtD
Iloperidone—Dry eye—Vandetanib—thyroid cancer	0.00118	0.0127	CcSEcCtD
Iloperidone—Rhinorrhoea—Sorafenib—thyroid cancer	0.00107	0.0115	CcSEcCtD
Iloperidone—Dyspnoea exertional—Epirubicin—thyroid cancer	0.00106	0.0114	CcSEcCtD
Iloperidone—Endocrine disorder—Sorafenib—thyroid cancer	0.00104	0.0112	CcSEcCtD
Iloperidone—Dyspnoea exertional—Doxorubicin—thyroid cancer	0.000977	0.0105	CcSEcCtD
Iloperidone—Gastrooesophageal reflux disease—Sorafenib—thyroid cancer	0.000956	0.0103	CcSEcCtD
Iloperidone—Cardiac failure—Vandetanib—thyroid cancer	0.000952	0.0103	CcSEcCtD
Iloperidone—Lethargy—Vandetanib—thyroid cancer	0.000948	0.0102	CcSEcCtD
Iloperidone—Dehydration—Vandetanib—thyroid cancer	0.000864	0.00931	CcSEcCtD
Iloperidone—Hypokalaemia—Vandetanib—thyroid cancer	0.000845	0.00911	CcSEcCtD
Iloperidone—Nasopharyngitis—Vandetanib—thyroid cancer	0.000831	0.00895	CcSEcCtD
Iloperidone—Gastritis—Vandetanib—thyroid cancer	0.000822	0.00886	CcSEcCtD
Iloperidone—Mouth ulceration—Sorafenib—thyroid cancer	0.00078	0.00841	CcSEcCtD
Iloperidone—Gynaecomastia—Sorafenib—thyroid cancer	0.000772	0.00832	CcSEcCtD
Iloperidone—Dysuria—Vandetanib—thyroid cancer	0.000751	0.00809	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.000746	0.00804	CcSEcCtD
Iloperidone—Pollakiuria—Vandetanib—thyroid cancer	0.000742	0.00799	CcSEcCtD
Iloperidone—Weight decreased—Vandetanib—thyroid cancer	0.000726	0.00783	CcSEcCtD
Iloperidone—Stomatitis—Vandetanib—thyroid cancer	0.000698	0.00752	CcSEcCtD
Iloperidone—Conjunctivitis—Vandetanib—thyroid cancer	0.000696	0.0075	CcSEcCtD
Iloperidone—Aphthous stomatitis—Epirubicin—thyroid cancer	0.00068	0.00733	CcSEcCtD
Iloperidone—Renal failure acute—Sorafenib—thyroid cancer	0.000679	0.00731	CcSEcCtD
Iloperidone—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000677	0.0073	CcSEcCtD
Iloperidone—Epistaxis—Vandetanib—thyroid cancer	0.000675	0.00728	CcSEcCtD
Iloperidone—Cardiac failure—Sorafenib—thyroid cancer	0.000642	0.00692	CcSEcCtD
Iloperidone—Urinary tract disorder—Vandetanib—thyroid cancer	0.000635	0.00684	CcSEcCtD
Iloperidone—Urethral disorder—Vandetanib—thyroid cancer	0.00063	0.00679	CcSEcCtD
Iloperidone—Aphthous stomatitis—Doxorubicin—thyroid cancer	0.000629	0.00678	CcSEcCtD
Iloperidone—Eye disorder—Vandetanib—thyroid cancer	0.0006	0.00647	CcSEcCtD
Iloperidone—Cardiac disorder—Vandetanib—thyroid cancer	0.000596	0.00643	CcSEcCtD
Iloperidone—Mood swings—Sorafenib—thyroid cancer	0.000594	0.0064	CcSEcCtD
Iloperidone—Angiopathy—Vandetanib—thyroid cancer	0.000583	0.00628	CcSEcCtD
Iloperidone—Dehydration—Sorafenib—thyroid cancer	0.000583	0.00628	CcSEcCtD
Iloperidone—Mediastinal disorder—Vandetanib—thyroid cancer	0.000579	0.00624	CcSEcCtD
Iloperidone—Arrhythmia—Vandetanib—thyroid cancer	0.000574	0.00619	CcSEcCtD
Iloperidone—Hypokalaemia—Sorafenib—thyroid cancer	0.00057	0.00615	CcSEcCtD
Iloperidone—Breast disorder—Sorafenib—thyroid cancer	0.000566	0.0061	CcSEcCtD
Iloperidone—Mental disorder—Vandetanib—thyroid cancer	0.000563	0.00607	CcSEcCtD
Iloperidone—Nasopharyngitis—Sorafenib—thyroid cancer	0.00056	0.00604	CcSEcCtD
Iloperidone—Malnutrition—Vandetanib—thyroid cancer	0.000559	0.00603	CcSEcCtD
Iloperidone—Gastritis—Sorafenib—thyroid cancer	0.000554	0.00598	CcSEcCtD
Iloperidone—Muscle spasms—Vandetanib—thyroid cancer	0.000538	0.0058	CcSEcCtD
Iloperidone—Vision blurred—Vandetanib—thyroid cancer	0.000527	0.00568	CcSEcCtD
Iloperidone—Tremor—Vandetanib—thyroid cancer	0.000524	0.00565	CcSEcCtD
Iloperidone—Abdominal discomfort—Sorafenib—thyroid cancer	0.000519	0.00559	CcSEcCtD
Iloperidone—Erectile dysfunction—Sorafenib—thyroid cancer	0.000499	0.00538	CcSEcCtD
Iloperidone—Weight decreased—Sorafenib—thyroid cancer	0.00049	0.00528	CcSEcCtD
Iloperidone—Arthralgia—Vandetanib—thyroid cancer	0.000476	0.00513	CcSEcCtD
Iloperidone—Stomatitis—Sorafenib—thyroid cancer	0.000471	0.00507	CcSEcCtD
Iloperidone—Dry mouth—Vandetanib—thyroid cancer	0.000466	0.00502	CcSEcCtD
Iloperidone—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000457	0.00492	CcSEcCtD
Iloperidone—Oedema—Vandetanib—thyroid cancer	0.000456	0.00492	CcSEcCtD
Iloperidone—Epistaxis—Sorafenib—thyroid cancer	0.000455	0.00491	CcSEcCtD
Iloperidone—Infection—Vandetanib—thyroid cancer	0.000454	0.00489	CcSEcCtD
Iloperidone—Nervous system disorder—Vandetanib—thyroid cancer	0.000448	0.00482	CcSEcCtD
Iloperidone—Nystagmus—Epirubicin—thyroid cancer	0.000447	0.00481	CcSEcCtD
Iloperidone—Urinary tract disorder—Sorafenib—thyroid cancer	0.000428	0.00461	CcSEcCtD
Iloperidone—Connective tissue disorder—Sorafenib—thyroid cancer	0.000426	0.00459	CcSEcCtD
Iloperidone—Urethral disorder—Sorafenib—thyroid cancer	0.000425	0.00458	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000416	0.00448	CcSEcCtD
Iloperidone—Nystagmus—Doxorubicin—thyroid cancer	0.000413	0.00445	CcSEcCtD
Iloperidone—Paraesthesia—Vandetanib—thyroid cancer	0.00041	0.00442	CcSEcCtD
Iloperidone—Dyspnoea—Vandetanib—thyroid cancer	0.000407	0.00439	CcSEcCtD
Iloperidone—Tinnitus—Sorafenib—thyroid cancer	0.000404	0.00436	CcSEcCtD
Iloperidone—Cardiac disorder—Sorafenib—thyroid cancer	0.000402	0.00434	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000394	0.00425	CcSEcCtD
Iloperidone—Fatigue—Vandetanib—thyroid cancer	0.000394	0.00424	CcSEcCtD
Iloperidone—Angiopathy—Sorafenib—thyroid cancer	0.000393	0.00424	CcSEcCtD
Iloperidone—Mediastinal disorder—Sorafenib—thyroid cancer	0.000391	0.00421	CcSEcCtD
Iloperidone—Arrhythmia—Sorafenib—thyroid cancer	0.000387	0.00417	CcSEcCtD
Iloperidone—Blood disorder—Epirubicin—thyroid cancer	0.000382	0.00412	CcSEcCtD
Iloperidone—Mental disorder—Sorafenib—thyroid cancer	0.00038	0.00409	CcSEcCtD
Iloperidone—Malnutrition—Sorafenib—thyroid cancer	0.000377	0.00407	CcSEcCtD
Iloperidone—Delirium—Epirubicin—thyroid cancer	0.000371	0.004	CcSEcCtD
Iloperidone—Breast pain—Epirubicin—thyroid cancer	0.000366	0.00394	CcSEcCtD
Iloperidone—Amenorrhoea—Epirubicin—thyroid cancer	0.000363	0.00391	CcSEcCtD
Iloperidone—Muscle spasms—Sorafenib—thyroid cancer	0.000363	0.00391	CcSEcCtD
Iloperidone—Body temperature increased—Vandetanib—thyroid cancer	0.000361	0.00389	CcSEcCtD
Iloperidone—Blood disorder—Doxorubicin—thyroid cancer	0.000353	0.00381	CcSEcCtD
Iloperidone—Anaemia—Sorafenib—thyroid cancer	0.000349	0.00376	CcSEcCtD
Iloperidone—Delirium—Doxorubicin—thyroid cancer	0.000343	0.0037	CcSEcCtD
Iloperidone—Dyskinesia—Epirubicin—thyroid cancer	0.000339	0.00366	CcSEcCtD
Iloperidone—Breast pain—Doxorubicin—thyroid cancer	0.000338	0.00365	CcSEcCtD
Iloperidone—Leukopenia—Sorafenib—thyroid cancer	0.000338	0.00364	CcSEcCtD
Iloperidone—Amenorrhoea—Doxorubicin—thyroid cancer	0.000336	0.00362	CcSEcCtD
Iloperidone—Asthenia—Vandetanib—thyroid cancer	0.000328	0.00353	CcSEcCtD
Iloperidone—Gait disturbance—Epirubicin—thyroid cancer	0.000327	0.00352	CcSEcCtD
Iloperidone—Arthralgia—Sorafenib—thyroid cancer	0.000321	0.00346	CcSEcCtD
Iloperidone—Myalgia—Sorafenib—thyroid cancer	0.000321	0.00346	CcSEcCtD
Iloperidone—Dry mouth—Sorafenib—thyroid cancer	0.000314	0.00339	CcSEcCtD
Iloperidone—Dyskinesia—Doxorubicin—thyroid cancer	0.000314	0.00338	CcSEcCtD
Iloperidone—Diarrhoea—Vandetanib—thyroid cancer	0.000312	0.00337	CcSEcCtD
Iloperidone—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00031	0.00334	CcSEcCtD
Iloperidone—Infection—Sorafenib—thyroid cancer	0.000306	0.0033	CcSEcCtD
Iloperidone—Fluid retention—Epirubicin—thyroid cancer	0.000303	0.00326	CcSEcCtD
Iloperidone—Gait disturbance—Doxorubicin—thyroid cancer	0.000302	0.00326	CcSEcCtD
Iloperidone—Nervous system disorder—Sorafenib—thyroid cancer	0.000302	0.00325	CcSEcCtD
Iloperidone—Dizziness—Vandetanib—thyroid cancer	0.000302	0.00325	CcSEcCtD
Iloperidone—Dry eye—Epirubicin—thyroid cancer	0.000295	0.00318	CcSEcCtD
Iloperidone—Mouth ulceration—Epirubicin—thyroid cancer	0.000288	0.00311	CcSEcCtD
Iloperidone—Rash—Vandetanib—thyroid cancer	0.000288	0.0031	CcSEcCtD
Iloperidone—Dermatitis—Vandetanib—thyroid cancer	0.000288	0.0031	CcSEcCtD
Iloperidone—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.000287	0.00309	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000281	0.00302	CcSEcCtD
Iloperidone—Fluid retention—Doxorubicin—thyroid cancer	0.00028	0.00302	CcSEcCtD
Iloperidone—Dyspnoea—Sorafenib—thyroid cancer	0.000275	0.00296	CcSEcCtD
Iloperidone—Dry eye—Doxorubicin—thyroid cancer	0.000273	0.00294	CcSEcCtD
Iloperidone—Nausea—Vandetanib—thyroid cancer	0.000271	0.00292	CcSEcCtD
Iloperidone—Mouth ulceration—Doxorubicin—thyroid cancer	0.000267	0.00288	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000266	0.00287	CcSEcCtD
Iloperidone—Fatigue—Sorafenib—thyroid cancer	0.000265	0.00286	CcSEcCtD
Iloperidone—Renal failure acute—Epirubicin—thyroid cancer	0.000251	0.0027	CcSEcCtD
Iloperidone—Increased appetite—Epirubicin—thyroid cancer	0.000246	0.00266	CcSEcCtD
Iloperidone—Body temperature increased—Sorafenib—thyroid cancer	0.000243	0.00262	CcSEcCtD
Iloperidone—Cardiac failure—Epirubicin—thyroid cancer	0.000237	0.00256	CcSEcCtD
Iloperidone—Lethargy—Epirubicin—thyroid cancer	0.000236	0.00255	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—thyroid cancer	0.000232	0.0025	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—thyroid cancer	0.000228	0.00246	CcSEcCtD
Iloperidone—Affect lability—Epirubicin—thyroid cancer	0.000228	0.00246	CcSEcCtD
Iloperidone—Asthenia—Sorafenib—thyroid cancer	0.000221	0.00238	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—thyroid cancer	0.00022	0.00237	CcSEcCtD
Iloperidone—Mood swings—Epirubicin—thyroid cancer	0.000219	0.00236	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—thyroid cancer	0.000219	0.00236	CcSEcCtD
Iloperidone—Dehydration—Epirubicin—thyroid cancer	0.000215	0.00232	CcSEcCtD
Iloperidone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000211	0.00228	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—thyroid cancer	0.000211	0.00227	CcSEcCtD
Iloperidone—Hypokalaemia—Epirubicin—thyroid cancer	0.000211	0.00227	CcSEcCtD
Iloperidone—Diarrhoea—Sorafenib—thyroid cancer	0.000211	0.00227	CcSEcCtD
Iloperidone—Breast disorder—Epirubicin—thyroid cancer	0.000209	0.00226	CcSEcCtD
Iloperidone—Nasopharyngitis—Epirubicin—thyroid cancer	0.000207	0.00223	CcSEcCtD
Iloperidone—Gastritis—Epirubicin—thyroid cancer	0.000205	0.00221	CcSEcCtD
Iloperidone—Dizziness—Sorafenib—thyroid cancer	0.000204	0.00219	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—thyroid cancer	0.000203	0.00219	CcSEcCtD
Iloperidone—Asthma—Epirubicin—thyroid cancer	0.0002	0.00216	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—thyroid cancer	0.000199	0.00215	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000196	0.00211	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—thyroid cancer	0.000195	0.0021	CcSEcCtD
Iloperidone—Rash—Sorafenib—thyroid cancer	0.000194	0.00209	CcSEcCtD
Iloperidone—Dermatitis—Sorafenib—thyroid cancer	0.000194	0.00209	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—thyroid cancer	0.000194	0.00209	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000192	0.00206	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—thyroid cancer	0.00019	0.00204	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—thyroid cancer	0.000187	0.00202	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000186	0.002	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—thyroid cancer	0.000185	0.002	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—thyroid cancer	0.000185	0.00199	CcSEcCtD
Iloperidone—Nausea—Sorafenib—thyroid cancer	0.000183	0.00197	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—thyroid cancer	0.000182	0.00196	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—thyroid cancer	0.000181	0.00195	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—thyroid cancer	0.000174	0.00187	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—thyroid cancer	0.000173	0.00187	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—thyroid cancer	0.000173	0.00187	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000172	0.00185	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—thyroid cancer	0.000171	0.00184	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000169	0.00182	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—thyroid cancer	0.000169	0.00182	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—thyroid cancer	0.000168	0.00181	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—thyroid cancer	0.000168	0.00181	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—thyroid cancer	0.000161	0.00173	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—thyroid cancer	0.00016	0.00173	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—thyroid cancer	0.000158	0.0017	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000157	0.0017	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—thyroid cancer	0.000157	0.00169	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000156	0.00168	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—thyroid cancer	0.000156	0.00168	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—thyroid cancer	0.00015	0.00161	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—thyroid cancer	0.000149	0.00161	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—thyroid cancer	0.000149	0.0016	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000146	0.00158	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000146	0.00157	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—thyroid cancer	0.000145	0.00157	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—thyroid cancer	0.000145	0.00157	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—thyroid cancer	0.000144	0.00156	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—thyroid cancer	0.000143	0.00154	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—thyroid cancer	0.00014	0.00151	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—thyroid cancer	0.000139	0.0015	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—thyroid cancer	0.000139	0.00149	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—thyroid cancer	0.000138	0.00149	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—thyroid cancer	0.000138	0.00148	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—thyroid cancer	0.000134	0.00145	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—thyroid cancer	0.000134	0.00144	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000134	0.00144	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—thyroid cancer	0.000132	0.00143	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—thyroid cancer	0.000131	0.00142	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—thyroid cancer	0.00013	0.0014	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—thyroid cancer	0.000129	0.00139	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—thyroid cancer	0.000129	0.00139	CcSEcCtD
Iloperidone—Agitation—Epirubicin—thyroid cancer	0.000128	0.00138	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—thyroid cancer	0.000125	0.00135	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—thyroid cancer	0.000125	0.00135	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—thyroid cancer	0.000124	0.00134	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—thyroid cancer	0.000123	0.00133	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—thyroid cancer	0.000122	0.00131	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—thyroid cancer	0.000119	0.00129	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—thyroid cancer	0.000119	0.00128	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—thyroid cancer	0.000119	0.00128	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—thyroid cancer	0.000119	0.00128	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—thyroid cancer	0.000116	0.00125	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—thyroid cancer	0.000116	0.00125	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—thyroid cancer	0.000115	0.00124	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—thyroid cancer	0.000115	0.00124	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—thyroid cancer	0.000114	0.00123	CcSEcCtD
Iloperidone—Oedema—Epirubicin—thyroid cancer	0.000114	0.00123	CcSEcCtD
Iloperidone—Infection—Epirubicin—thyroid cancer	0.000113	0.00122	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—thyroid cancer	0.000112	0.0012	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—thyroid cancer	0.000111	0.0012	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—thyroid cancer	0.00011	0.00118	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—thyroid cancer	0.00011	0.00118	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—thyroid cancer	0.000107	0.00116	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—thyroid cancer	0.000106	0.00115	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—thyroid cancer	0.000106	0.00114	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—thyroid cancer	0.000105	0.00113	CcSEcCtD
Iloperidone—Infection—Doxorubicin—thyroid cancer	0.000105	0.00113	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000104	0.00112	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—thyroid cancer	0.000103	0.00111	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—thyroid cancer	0.000103	0.00111	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—thyroid cancer	0.000102	0.0011	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—thyroid cancer	0.000101	0.00109	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—thyroid cancer	0.000101	0.00109	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—thyroid cancer	9.84e-05	0.00106	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—thyroid cancer	9.83e-05	0.00106	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—thyroid cancer	9.81e-05	0.00106	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	9.59e-05	0.00103	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—thyroid cancer	9.46e-05	0.00102	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—thyroid cancer	9.39e-05	0.00101	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—thyroid cancer	9.38e-05	0.00101	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—thyroid cancer	9.36e-05	0.00101	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	9.09e-05	0.00098	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—thyroid cancer	9.08e-05	0.000978	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—thyroid cancer	9e-05	0.00097	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—thyroid cancer	8.68e-05	0.000935	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—thyroid cancer	8.32e-05	0.000897	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—thyroid cancer	8.17e-05	0.00088	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—thyroid cancer	7.79e-05	0.000839	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—thyroid cancer	7.55e-05	0.000814	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—thyroid cancer	7.53e-05	0.000811	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—thyroid cancer	7.2e-05	0.000776	CcSEcCtD
Iloperidone—Rash—Epirubicin—thyroid cancer	7.18e-05	0.000773	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—thyroid cancer	7.17e-05	0.000773	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—thyroid cancer	6.96e-05	0.00075	CcSEcCtD
Iloperidone—Nausea—Epirubicin—thyroid cancer	6.76e-05	0.000729	CcSEcCtD
Iloperidone—Rash—Doxorubicin—thyroid cancer	6.64e-05	0.000716	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—thyroid cancer	6.63e-05	0.000715	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—thyroid cancer	6.25e-05	0.000674	CcSEcCtD
Iloperidone—HTR6—Signaling Pathways—BRAF—thyroid cancer	6.22e-06	0.000288	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—BRAF—thyroid cancer	6.21e-06	0.000287	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—TPR—thyroid cancer	6.17e-06	0.000286	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—BRAF—thyroid cancer	6.17e-06	0.000285	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	6.07e-06	0.000281	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—HRAS—thyroid cancer	6.04e-06	0.000279	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—BRAF—thyroid cancer	5.94e-06	0.000275	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TERT—thyroid cancer	5.81e-06	0.000269	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TERT—thyroid cancer	5.78e-06	0.000267	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—KRAS—thyroid cancer	5.77e-06	0.000267	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—NRAS—thyroid cancer	5.69e-06	0.000263	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—KRAS—thyroid cancer	5.69e-06	0.000263	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—KRAS—thyroid cancer	5.68e-06	0.000263	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRG1—thyroid cancer	5.68e-06	0.000263	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—KRAS—thyroid cancer	5.65e-06	0.000261	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PPARG—thyroid cancer	5.63e-06	0.000261	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TERT—thyroid cancer	5.62e-06	0.00026	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—NRAS—thyroid cancer	5.62e-06	0.00026	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRG1—thyroid cancer	5.59e-06	0.000259	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRG1—thyroid cancer	5.58e-06	0.000258	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	5.56e-06	0.000257	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	5.53e-06	0.000256	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.5e-06	0.000255	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	5.47e-06	0.000253	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PPARG—thyroid cancer	5.47e-06	0.000253	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—SLC5A5—thyroid cancer	5.45e-06	0.000252	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—KRAS—thyroid cancer	5.44e-06	0.000252	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HIF1A—thyroid cancer	5.38e-06	0.000249	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—BRAF—thyroid cancer	5.35e-06	0.000248	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—AKT1—thyroid cancer	5.33e-06	0.000247	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—BRAF—thyroid cancer	5.28e-06	0.000244	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—TP53—thyroid cancer	5.13e-06	0.000237	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TERT—thyroid cancer	5.1e-06	0.000236	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	5.09e-06	0.000235	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TERT—thyroid cancer	5.02e-06	0.000232	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TERT—thyroid cancer	5.01e-06	0.000232	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TERT—thyroid cancer	4.91e-06	0.000227	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—HRAS—thyroid cancer	4.9e-06	0.000227	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—KRAS—thyroid cancer	4.9e-06	0.000227	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	4.89e-06	0.000227	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HIF1A—thyroid cancer	4.88e-06	0.000226	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	4.87e-06	0.000225	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—HRAS—thyroid cancer	4.84e-06	0.000224	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—KRAS—thyroid cancer	4.83e-06	0.000224	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—HRAS—thyroid cancer	4.83e-06	0.000224	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	4.8e-06	0.000222	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	4.8e-06	0.000222	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HIF1A—thyroid cancer	4.79e-06	0.000222	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—TPR—thyroid cancer	4.76e-06	0.00022	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—NRAS—thyroid cancer	4.74e-06	0.000219	CbGpPWpGaD
Iloperidone—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	4.7e-06	0.000218	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	4.7e-06	0.000218	CbGpPWpGaD
Iloperidone—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	4.7e-06	0.000217	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.69e-06	0.000217	CbGpPWpGaD
Iloperidone—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	4.67e-06	0.000216	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—HRAS—thyroid cancer	4.63e-06	0.000214	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—SLC5A5—thyroid cancer	4.62e-06	0.000214	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—BRAF—thyroid cancer	4.6e-06	0.000213	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—RXRA—thyroid cancer	4.58e-06	0.000212	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—BRAF—thyroid cancer	4.58e-06	0.000212	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TERT—thyroid cancer	4.57e-06	0.000211	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—CCND1—thyroid cancer	4.54e-06	0.00021	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—CCND1—thyroid cancer	4.53e-06	0.00021	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—CCND1—thyroid cancer	4.5e-06	0.000208	CbGpPWpGaD
Iloperidone—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	4.5e-06	0.000208	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	4.45e-06	0.000206	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PPARG—thyroid cancer	4.44e-06	0.000206	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTGS2—thyroid cancer	4.43e-06	0.000205	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—PTEN—thyroid cancer	4.38e-06	0.000203	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—PTEN—thyroid cancer	4.37e-06	0.000202	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	4.37e-06	0.000202	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—PTEN—thyroid cancer	4.34e-06	0.000201	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—CCND1—thyroid cancer	4.34e-06	0.000201	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—AKT1—thyroid cancer	4.33e-06	0.0002	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.33e-06	0.0002	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTGS2—thyroid cancer	4.3e-06	0.000199	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—NRAS—thyroid cancer	4.3e-06	0.000199	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—AKT1—thyroid cancer	4.27e-06	0.000198	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—AKT1—thyroid cancer	4.27e-06	0.000197	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	4.24e-06	0.000196	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	4.23e-06	0.000196	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—NRAS—thyroid cancer	4.22e-06	0.000195	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	4.21e-06	0.000195	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	4.19e-06	0.000194	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PTEN—thyroid cancer	4.19e-06	0.000194	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—HRAS—thyroid cancer	4.16e-06	0.000193	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	4.14e-06	0.000192	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—HRAS—thyroid cancer	4.11e-06	0.00019	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—AKT1—thyroid cancer	4.08e-06	0.000189	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PPARG—thyroid cancer	4.08e-06	0.000189	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	4.08e-06	0.000189	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PPARG—thyroid cancer	4.07e-06	0.000188	CbGpPWpGaD
Iloperidone—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	4.05e-06	0.000187	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—BRAF—thyroid cancer	4.04e-06	0.000187	CbGpPWpGaD
Iloperidone—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	4e-06	0.000185	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—BRAF—thyroid cancer	3.97e-06	0.000184	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—BRAF—thyroid cancer	3.97e-06	0.000184	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—NRAS—thyroid cancer	3.91e-06	0.000181	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CCND1—thyroid cancer	3.9e-06	0.000181	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—NRAS—thyroid cancer	3.9e-06	0.000181	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	3.89e-06	0.00018	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—RXRA—thyroid cancer	3.88e-06	0.00018	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—NRAS—thyroid cancer	3.88e-06	0.000179	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTEN—thyroid cancer	3.86e-06	0.000179	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CCND1—thyroid cancer	3.85e-06	0.000178	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	3.85e-06	0.000178	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.78e-06	0.000175	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PTEN—thyroid cancer	3.77e-06	0.000174	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTEN—thyroid cancer	3.75e-06	0.000174	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—NRAS—thyroid cancer	3.74e-06	0.000173	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PTEN—thyroid cancer	3.72e-06	0.000172	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—KRAS—thyroid cancer	3.7e-06	0.000171	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—AKT1—thyroid cancer	3.68e-06	0.00017	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	3.64e-06	0.000168	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—KRAS—thyroid cancer	3.63e-06	0.000168	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—AKT1—thyroid cancer	3.63e-06	0.000168	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	3.62e-06	0.000167	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	3.58e-06	0.000166	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.57e-06	0.000165	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	3.56e-06	0.000165	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	3.56e-06	0.000165	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—thyroid cancer	3.49e-06	0.000162	CbGpPWpGaD
Iloperidone—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	3.48e-06	0.000161	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	3.46e-06	0.00016	CbGpPWpGaD
Iloperidone—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	3.46e-06	0.00016	CbGpPWpGaD
Iloperidone—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	3.37e-06	0.000156	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—NRAS—thyroid cancer	3.36e-06	0.000156	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—KRAS—thyroid cancer	3.36e-06	0.000156	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—KRAS—thyroid cancer	3.36e-06	0.000155	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CCND1—thyroid cancer	3.36e-06	0.000155	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCND1—thyroid cancer	3.34e-06	0.000155	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KRAS—thyroid cancer	3.34e-06	0.000154	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NRAS—thyroid cancer	3.32e-06	0.000154	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	3.31e-06	0.000153	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	3.25e-06	0.00015	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTEN—thyroid cancer	3.24e-06	0.00015	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTEN—thyroid cancer	3.22e-06	0.000149	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KRAS—thyroid cancer	3.21e-06	0.000149	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—thyroid cancer	3.21e-06	0.000148	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—thyroid cancer	3.2e-06	0.000148	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	3.16e-06	0.000146	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	3.15e-06	0.000146	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—HRAS—thyroid cancer	3.14e-06	0.000146	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	3.14e-06	0.000145	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	3.09e-06	0.000143	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—HRAS—thyroid cancer	3.09e-06	0.000143	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	3.06e-06	0.000142	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	3.06e-06	0.000141	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTEN—thyroid cancer	3.05e-06	0.000141	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	3.03e-06	0.00014	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	3.01e-06	0.000139	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	3e-06	0.000139	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—RXRA—thyroid cancer	3e-06	0.000139	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—thyroid cancer	2.99e-06	0.000138	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—thyroid cancer	2.98e-06	0.000138	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—thyroid cancer	2.97e-06	0.000137	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—thyroid cancer	2.95e-06	0.000136	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	2.95e-06	0.000136	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—thyroid cancer	2.9e-06	0.000134	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—thyroid cancer	2.89e-06	0.000134	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—thyroid cancer	2.89e-06	0.000134	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARG—thyroid cancer	2.89e-06	0.000134	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NRAS—thyroid cancer	2.89e-06	0.000134	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NRAS—thyroid cancer	2.88e-06	0.000133	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—thyroid cancer	2.86e-06	0.000132	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—thyroid cancer	2.86e-06	0.000132	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—thyroid cancer	2.86e-06	0.000132	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—thyroid cancer	2.85e-06	0.000132	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—thyroid cancer	2.85e-06	0.000132	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	2.84e-06	0.000131	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—thyroid cancer	2.84e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	2.81e-06	0.00013	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—thyroid cancer	2.8e-06	0.00013	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	2.8e-06	0.000129	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—thyroid cancer	2.8e-06	0.000129	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—thyroid cancer	2.79e-06	0.000129	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—thyroid cancer	2.79e-06	0.000129	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—thyroid cancer	2.78e-06	0.000128	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	2.74e-06	0.000127	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	2.74e-06	0.000127	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—thyroid cancer	2.73e-06	0.000126	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	2.73e-06	0.000126	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—thyroid cancer	2.73e-06	0.000126	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	2.67e-06	0.000124	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	2.64e-06	0.000122	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—thyroid cancer	2.57e-06	0.000119	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	2.55e-06	0.000118	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRAS—thyroid cancer	2.54e-06	0.000117	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—thyroid cancer	2.54e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—thyroid cancer	2.52e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—thyroid cancer	2.52e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—thyroid cancer	2.5e-06	0.000116	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRAS—thyroid cancer	2.5e-06	0.000116	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRAS—thyroid cancer	2.49e-06	0.000115	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—thyroid cancer	2.49e-06	0.000115	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	2.49e-06	0.000115	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—thyroid cancer	2.48e-06	0.000115	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—thyroid cancer	2.46e-06	0.000114	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARG—thyroid cancer	2.45e-06	0.000113	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	2.45e-06	0.000113	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—thyroid cancer	2.43e-06	0.000112	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—thyroid cancer	2.41e-06	0.000112	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	2.41e-06	0.000111	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.28e-06	0.000105	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	2.27e-06	0.000105	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—thyroid cancer	2.23e-06	0.000103	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—thyroid cancer	2.21e-06	0.000102	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—thyroid cancer	2.2e-06	0.000102	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—thyroid cancer	2.19e-06	0.000101	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—thyroid cancer	2.17e-06	0.000101	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—thyroid cancer	2.16e-06	0.0001	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—thyroid cancer	2.15e-06	9.95e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—thyroid cancer	2.15e-06	9.93e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—thyroid cancer	2.14e-06	9.92e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—thyroid cancer	2.14e-06	9.91e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—thyroid cancer	2.12e-06	9.79e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	2.11e-06	9.74e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—thyroid cancer	2.1e-06	9.74e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	2.05e-06	9.47e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—thyroid cancer	1.99e-06	9.19e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	1.96e-06	9.05e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—thyroid cancer	1.94e-06	8.99e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—thyroid cancer	1.93e-06	8.92e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—thyroid cancer	1.91e-06	8.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—thyroid cancer	1.91e-06	8.82e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARG—thyroid cancer	1.89e-06	8.76e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—thyroid cancer	1.87e-06	8.66e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—thyroid cancer	1.87e-06	8.64e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—thyroid cancer	1.86e-06	8.6e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—thyroid cancer	1.86e-06	8.6e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—thyroid cancer	1.83e-06	8.46e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—thyroid cancer	1.82e-06	8.44e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	1.81e-06	8.36e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	1.79e-06	8.28e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—thyroid cancer	1.76e-06	8.13e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—thyroid cancer	1.74e-06	8.05e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—thyroid cancer	1.68e-06	7.78e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	1.66e-06	7.69e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—thyroid cancer	1.64e-06	7.59e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—thyroid cancer	1.61e-06	7.47e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—thyroid cancer	1.61e-06	7.46e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—thyroid cancer	1.61e-06	7.45e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—thyroid cancer	1.61e-06	7.45e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	1.58e-06	7.31e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.49e-06	6.89e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	1.47e-06	6.79e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—thyroid cancer	1.3e-06	6.01e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—thyroid cancer	1.14e-06	5.29e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—thyroid cancer	9.69e-07	4.49e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—thyroid cancer	7.48e-07	3.46e-05	CbGpPWpGaD
